Ascletis Pharma Inc
HKEX:1672
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.78
1.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ascletis Pharma Inc
Ascletis Pharma Inc
PP&E Net
Ascletis Pharma Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascletis Pharma Inc
HKEX:1672
|
PP&E Net
¥68.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
PP&E Net
¥9.3B
|
CAGR 3-Years
54%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
PP&E Net
¥2.4B
|
CAGR 3-Years
41%
|
CAGR 5-Years
66%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
PP&E Net
¥2.9B
|
CAGR 3-Years
46%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
PP&E Net
¥1.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
PP&E Net
¥5.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
Ascletis Pharma Inc
Glance View
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
See Also
What is Ascletis Pharma Inc's PP&E Net?
PP&E Net
68.5m
CNY
Based on the financial report for Dec 31, 2023, Ascletis Pharma Inc's PP&E Net amounts to 68.5m CNY.
What is Ascletis Pharma Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
-5%
Over the last year, the PP&E Net growth was -6%. The average annual PP&E Net growth rates for Ascletis Pharma Inc have been -7% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
